share_log

Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics

Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics

預測未來:Viridian Therapeutics的13位分析師預測
Benzinga ·  09/26 14:00
Analysts' ratings for Viridian Therapeutics (NASDAQ:VRDN) over the last quarter vary from bullish to bearish, as provided by 13 analysts.
過去一個季度,13位分析師對Viridian Therapeutics(納斯達克股票代碼:VRDN)的評級從看好到看淡不一。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中,您將找到他們最近的評級摘要,揭示了過去30天內情緒的變化,並將它們與前幾個月進行比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $37.69, a high estimate of $61.00, and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 7.69% from the previous average price target of $35.00.
由分析師分析得出的12個月目標價提供了洞察,平均目標價爲37.69美元,最高估值爲61.00美元,最低估值爲27.00美元。目前的平均值呈現積極變化,比以前的平均目標價35.00美元上升了7.69%。
Deciphering Analyst Ratings: An In-Depth Analysis
分析師評級解讀:深入分析
The standing of Viridian Therapeutics...
通過對最近...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論